April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Characteristics Related to Baseline Visual Acuity in a Multicenter, Randomized, Sham-Controlled Trial of an Applicator-Delivered Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in Patients with Macular Edema due to Retinal Vein Occlusion
Author Affiliations & Notes
  • S. M. Whitcup
    Allergan, Inc, Irvine, California
  • J. Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts
  • J. Haller
    Wills Eye Institute, Philadelphia, Pennsylvania
  • M.-L. Jacques
    Allergan, Inc, Irvine, California
  • X.-Y. Li
    Allergan, Inc, Irvine, California
  • H. Cui
    Allergan, Inc, Irvine, California
  • Posurdex RVO Study Group
    Allergan, Inc, Irvine, California
  • Footnotes
    Commercial Relationships  S.M. Whitcup, Allergan, Inc, E; J. Heier, Allergan, C; Genentech, C; Ista, C; J. Haller, Allergan, C; M.-L. Jacques, Allergan, E; X.-Y. Li, Allergan, E; H. Cui, Allergan, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5407. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. M. Whitcup, J. Heier, J. Haller, M.-L. Jacques, X.-Y. Li, H. Cui, Posurdex RVO Study Group; Characteristics Related to Baseline Visual Acuity in a Multicenter, Randomized, Sham-Controlled Trial of an Applicator-Delivered Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in Patients with Macular Edema due to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5407.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine characteristics related to baseline best-corrected visual acuity (BCVA) in a trial of applicator-delivered DEX PS DDS for the treatment of macular edema (ME) associated with central or branch retinal vein occlusion (RVO).

Methods: : In this multicenter, randomized, double-masked study, patients with ME (duration 1.5-9 months for CRVO; 1.5-12 months for BRVO) due to RVO were randomized to receive 350µg (n=218) or 700µg DEX PS DDS (n=226) or a sham procedure (n=224). Baseline characteristics evaluated included demographics; type, duration, and prior treatment of ME; BCVA; and retinal thickness as measured by OCT. Linear regression analysis was used to evaluate the relationship between baseline BCVA and other baseline characteristics.

Results: : Mean age was 64 years, 52% were male, 35% had CRVO and 65% had BRVO. Prior to study entry, 53% of patients had macular edema for 90-179 days, 6% had used medication for ME, and 9% had a procedure for ME. Mean baseline retinal thickness was 561 µm overall (CRVO = 640, BRVO = 518). Mean baseline BCVA was 54.4 letters overall, 52.0 for CRVO, and 55.6 for BRVO, and this difference in BCVA was statistically significant (BRVO vs CRVO; P=.006). In addition, baseline BCVA was significantly correlated with baseline retinal thickness (P<.001) and age (P≤.024) in the overall population, and both CRVO and BRVO subgroups. A 100-µm increase in retinal thickness was associated with decreased BCVA of 1.3 letters in all patients (CRVO = 1.5, BRVO = 1.1). Every 10 years of age increase was associated with decreased BCVA of 1.5 letters in all patients (CRVO = 1.2, BRVO = 1.7). There was no significant association between BCVA and gender, ME duration, or use of prior RVO treatments.

Conclusions: : In this study of patients with RVO, baseline BCVA was significantly associated with the type of RVO (central vs branch), retinal thickness, and age.

Clinical Trial: : www.clinicaltrials.gov NCT00168298

Keywords: vascular occlusion/vascular occlusive disease • macula/fovea • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×